Abstracts

EFFICACY OF Ad26/MVA + Env + VESATOLIMOD THERAPEUTIC VACCINATION IN RHESUS MACAQUES

Recent work assessing the immunogenicity and efficacy of therapeutic vaccination in SIV/SHIV infected rhesus macaques while on antiretroviral therapy (ART) has shown promise. We asked whether modifying a current adenovirus serotype 26 (Ad26) and modified vaccinia Ankara (MVA) therapeutic prime boost regimen expressing SIV Gag, Pol, and Env, in combination with the TLR7 agonist vesatolimod…

BEAT2: PEG-IFN-?2B + 3BNC117 AND 10-1074 KEEPS HIV AT

Broadly neutralizing anti-HIV monoclonal antibodies (bNAbs) have shown promising results for the prevention and treatment of HIV. We present the results of Step 3 of BEAT2 evaluating whether the combination of bNAbs 3BNC117 and 10-1074 plus peg-IFN-?2b can prevent or delay the return of viremia during 26 weeks of ART interruption (ATI). BEAT2 (NCT03588715) is…

SMAC MIMETICS REACTIVATE HIV AND REDUCE THE VIRAL RESERVOIR IN HUMANIZED MICE

Antiretroviral therapy (ART) suppresses HIV replication without eliminating viral reservoirs (VR). VR cells express high levels of Inhibitors of Apoptosis Proteins (IAPs), enabling their prolonged survival. PKC agonists, the most potent HIV latency reversing agents (LRA), reactivate VR via activation of canonical NF?B pathway, without VR elimination. However, since they are likely to greatly increase…

INDUCIBLE RESERVOIR IN TISSUES, BUT NOT IN PERIPHERY, PREDICTS FUNCTIONAL CURE OF SIV

HIV persistence in reservoirs requires lifelong antiretroviral therapy (ART), calling for cure. Latency reversing agents (LRAs), such as the histone deacetylase inhibitor romidepsin, reactivate and clear HIV/SIV through cell-mediated immune responses and viral lytic effects (‘shock and kill’). We tested a total of four single infusions and two ‘double infusions’ (two infusions separated by 48…

IDENTIFICATION OF SYNERGISTIC COMBINATIONS OF HIV SILENCING PROMOTING FACTORS

The activity of latent HIV is counter-regulated by both silencing and activating factors. To durably silence latent HIV (‘block-and-lock’), we will specifically define how to enhance the activity of synergistic repressors while neutralizing HIV activators in relevant host cells. In this research, we are systematically evaluating the combinations of recently identified silencing promoting factors (SPFs)…

POTENT TARGETED ACTIVATOR OF CELL KILL (TACK) MOLECULES ELIMINATE HIV-INFECTED CELLS

Strategies to address both latent and virus expressing cells that contribute to viral recrudescence upon ART cessation are required to achieve functional cure in people living with HIV-1 (PLWH). Some non-nucleoside reverse transcriptase inhibitors (NNRTIs) have a weak secondary activity that results in selective cytotoxicity by promoting dimerization of HIV-1 Gag-Pol and intracellular activation of…